Medtronic

Report: Global medtech sales forecast to reach $522B by 2022

Tuesday, September 26, 2017

The “EvaluateMedTech World Preview 2017, Outlook to 2022” report from life science commercial intelligence firm Evaluate, reveals Medtronic was the leading medtech company in 2016 with sales of almost $30 billion and will retain the crown in 2022, with sales forecast to reach $37.7 billion. Abbott to jump to 3rd place as its acquisition of St. Jude creates the world’s second largest cardiology company.

[Read More]

Cardinal Health to acquire Medtronic Patient Product Portfolio

Thursday, April 20, 2017

Cardinal Health has entered into a definitive agreement to acquire Medtronic‘s Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses for $6.1 billion in cash. The purchase price does not include cash tax benefits of at least $100 million. The acquisition is expected to be financed with a combination of $4.5 billion in new senior unsecured notes and existing cash. The transaction is expected to close in the first quarter of Cardinal Health’s fiscal year 2018, subject to customary closing conditions, including regulatory clearances.

[Read More]

St. Jude cybersecurity vulnerabilities spark medical device hacking debate

Monday, January 16, 2017

A recent cybersecurity scandal involving St. Jude’s Merlin@home device sparked a renewed discussion within the medical device industry about the best way to address security flaws discovered by independent security experts, sometimes called “white hat” hackers. As medical devices become increasingly vulnerable to cyber attack, the industry has broadly accepted its new responsibility of continuously protecting approved devices from potential security breaches.

[Read More]

An exciting year for the medical technology industry

Monday, December 19, 2016

The Pulse on Global Trials by Matthew Howes

In the medical technology industry, 2016 has been an exciting year for R&D. From the development of naturally moving prosthetic limbs that are controlled by the brain to the use of a needle-free vaccine delivery device in Zika trials, medical devices are becoming a major focus in the advancement of human health.

[Read More]

Optimal Strategix Group launches study matching app

Wednesday, September 16, 2015

Optimal Strategix Group (OSG), based in Newtown, Pa., has launched its CAVII app, available for download in the Apple App Store. CAVII is an iOS-based clinical study matching and analytics platform. Ushering in a new era of patient engagement, CAVII’s aim is to revolutionize clinical studies through the use of analytics for superior patient matching. Through CAVII, clinical studies could become more cost-effective, efficient and ultimately more engaging and insightful for patients and clinicians.

[Read More]